UNRESECTABLE TRIPLE-NEGATIVE BREAST CARCINOMA
Clinical trials for UNRESECTABLE TRIPLE-NEGATIVE BREAST CARCINOMA explained in plain language.
Never miss a new study
Get alerted when new UNRESECTABLE TRIPLE-NEGATIVE BREAST CARCINOMA trials appear
Sign up with your email to follow new studies for UNRESECTABLE TRIPLE-NEGATIVE BREAST CARCINOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
New drug cocktail shows promise for Tough-to-Treat breast cancer
Disease control OngoingThis study tests two drugs, eribulin and copanlisib, together in people with metastatic triple-negative breast cancer that has spread or cannot be removed. The goal is to find the safest dose and see if the combination helps stop or slow tumor growth. About 24 adults with this ag…
Matched conditions: UNRESECTABLE TRIPLE-NEGATIVE BREAST CARCINOMA
Phase: PHASE1, PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 19, 2026 11:59 UTC
-
New drug combo shows promise in Hard-to-Treat cancers
Disease control OngoingThis study tests a combination of two drugs, cediranib and olaparib, in people with advanced or inoperable solid tumors, including certain breast, lung, and pancreatic cancers. The goal is to see if the combo can shrink tumors or slow their growth by blocking enzymes that cancer …
Matched conditions: UNRESECTABLE TRIPLE-NEGATIVE BREAST CARCINOMA
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 08, 2026 12:04 UTC